SEARCH

SEARCH BY CITATION

References

  • 1
    Bateman ED. Severity and control of severe asthma. J Allergy Clin Immunol 2006;117:519521.
  • 2
    Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report. J Allergy Clin Immunol 1991;88:425534.
  • 3
    GINA Report. Global strategy for asthma management and prevention. Revised 2006. http://www.ginasthma.com/guidelineitem.asp?? (Accessed 16 December 2006).
  • 4
    Kwok MY, Walsh-Kelly CM, Gorelick MH, Grabowski L, Kelly KJ. National Asthma Education and Prevention Program severity classification as a measure of disease burden in children with acute asthma. Pediatrics 2006;117:S71S77.
  • 5
    Roche N, Morel H, Martel P, Godard P. Clinical practice guidelines: medical follow-up of patients with asthma – adults and adolescents. Respir Med 2005;99:793815.
  • 6
    Wenzel S. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804813.
  • 7
    Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP et al. Severe asthma: what are the important questions. J Allergy Clin Immunol, in press.
  • 8
    Guidelines for management of asthma in adults: I–Chronic persistent asthma. Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign [published erratum appears in BMJ 1990 Oct 20;301(6757):924]. BMJ 1990;301:651653.
  • 9
    Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999;161:S1S61.
  • 10
    Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA. Classifying asthma severity in children-mismatch between symptoms, medication use and lung function. Am J Respir Crit Care Med 2004;170:426432.
  • 11
    Li J, Oppehneimer J, Bernstein I, Nicklas R. Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005;116:S3S11.
  • 12
    Castro M, Bloch SR, Jenkerson MV, DeMartino S, Hamilos DL, Cochran RB et al. Asthma exacerbations after glucocorticoid withdrawal reflects T cell recruitment to the airway. Am J Respir Crit Care Med 2004;169:842849.
  • 13
    Gibson PG, Wong BJ, Hepperle MJ, Kline PA, Girgis-Gabardo A, Guyatt G et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992;22:525532.
  • 14
    Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? Am J Respir Crit Care Med 1995;151:13201325.
  • 15
    Woolcock AJ, Reddel H, Trevillion L. Assessment of airway responsiveness as a guide to diagnosis, prognosis, and therapy in asthma. Allergy Proc 1995;16:2326.
  • 16
    Spahn JD, Cherniack R, Paull K, Gelfand EW. Is forced expiratory volume in one second the best measure of severity in childhood asthma? Am J Respir Crit Care Med 2004;169:784786.
  • 17
    Jenkins C, Woolcock AJ, Saarelainen P, Lundback B, James MH. Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma. Respir Med 2000;94:715723.
  • 18
    Zetterstrom O, Buhl R, Mellem H, Perpina M, Hedman J, O'Neill S et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001;18:262268.
  • 19
    Baumgartner RA, Martinez G, Edelman JM, Rodriguez Gomez GG, Bernstein M, Bird S et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 2003;21:123128.
  • 20
    Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902907.
  • 21
    Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:5965.
  • 22
    Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998;114:9981007.
  • 23
    Vollmer WM, Markson LE, O'Connor E, Sanocki LL, Fitterman L, Berger M et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999;160:16471652.
  • 24
    Peters D, Chen C, Markson LE, Allen-Ramey FC, Vollmer WM. Using an asthma control questionnaire and administrative data to predict health-care utilization. Chest 2006;129:918924.
  • 25
    Boulet LP, Boulet V, Milot J. How should we quantify asthma control? A proposal. Chest 2002;122:22172223.
  • 26
    Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802807.
  • 27
    Lai CK, De Guia TS, Kim YY, Kuo SH, Mukhopadhyay A, Soriano JB et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol 2003;111:263268.
  • 28
    Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:4047.
  • 29
    Ressel GW. NAEPP updates guidelines for the diagnosis and management of asthma. Am Fam Physician 2003;68:169170.
  • 30
    Gustafsson PM, Watson L, Davis KJ, Rabe KF. Poor asthma control in children: evidence from epidemiological surveys and implications for clinical practice. Int J Clin Pract 2006;60:321334.
  • 31
    Cairns CB. Acute asthma exacerbations: phenotypes and management. Clin Chest Med 2006;27:99108.
  • 32
    Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [see comments]. N Engl J Med 1997;337:14051411.
  • 33
    Chan-Yeung M, Chang JH, Manfreda J, Ferguson A, Becker A. Changes in peak flow, symptom score, and the use of medications during acute exacerbations of asthma. Am J Respir Crit Care Med 1996;154:889893.
  • 34
    Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:17201745.
  • 35
    Sont JK, Willems LN, Bel EH, Van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159:10431051.
  • 36
    Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:17151721.
  • 37
    Jarayam L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483494.
  • 38
    Mahut B, Delclaux C, Tillie-Leblond I, Gosset P, Delacourt C, Zerah-Lancner F et al. Both inflammation and remodeling influence nitric oxide output in children with refractory asthma. J Allergy Clin Immunol 2004;113:252256.
  • 39
    Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:21632173.
  • 40
    Rosias PP, Dompeling E, Hendriks HJ, Heijnens JW, Donckerwolcke RA, Jobsis Q. Exhaled breath condensate in children: pearls and pitfalls. Pediatr Allergy Immunol 2004;15:419.
  • 41
    Janson SL, Fahy JV, Covington JK, Paul SM, Gold WM, Boushey HA. Effects of individual self-management education on clinical, biological, and adherence outcomes in asthma. Am J Med 2003;115:620626.
  • 42
    Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:25832593.
  • 43
    Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults–United States, 1998. MMWR Morb Mortal Wkly Rep 2000;49:881884.
  • 44
    Wakefield M, Ruffin R, Campbell D, Roberts L, Wilson D. Smoking-related beliefs and behaviour among adults with asthma in a representative population sample. Aust N Z J Med 1995;25:1217.
  • 45
    Eisner MD. Environmental tobacco smoke and adult asthma. Clin Chest Med 2002;23:749761.
  • 46
    Boulet LP, Lemiere C, Archambault F, Carrier G, Descarry MC, Deschesnes F. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest 2006;129:661668.
  • 47
    Eisner MD, Yelin EH, Henke J, Shiboski SC, Blanc PD. Environmental tobacco smoke and adult asthma. The impact of changing exposure status on health outcomes. Am J Respir Crit Care Med 1998;158:170175.
  • 48
    Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:11941200.
  • 49
    Bousquet J, Vignola AM. Exposure to environmental tobacco smoke and adult asthma. Allergy 2001;56:466469.
  • 50
    Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226230.
  • 51
    Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:13081311.
  • 52
    Thomson NC, Chaudhuri R, Livingston E. Active cigarette smoking and asthma. Clin Exp Allergy 2003;33:14711475.
  • 53
    Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001;120:19171922.
  • 54
    Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:11101112.
  • 55
    Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530534.
  • 56
    Gagliardo R, Chanez P, Mathieu M, Bruno A, Costanzo G, Gougat C et al. Persistent activation of nuclear factor-{kappa}B signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med 2003;168:11901198.
  • 57
    Minor TE, Baker JW, Dick EC, DeMeo AN, Ouellette JJ, Cohen M et al. Greater frequency of viral respiratory infections in asthmatic children as compared with their nonasthmatic siblings. J Pediatr 1974;85:472477.
  • 58
    Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ 1995;310:12251229.
  • 59
    Rakes GP, Arruda E, Ingram JM, Hoover GE, Zambrano JC, Hayden FG et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med 1999;159:785790.
  • 60
    Jacoby DB. Virus-induced asthma attacks. JAMA 2002;287:755761.
  • 61
    Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004;350:443450.
  • 62
    McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000;CD001107.
  • 63
    Rachelefsky G. Treating exacerbations of asthma in children: the role of systemic corticosteroids. Pediatrics 2003;112:382397.
  • 64
    Custovic A, Taggart SC, Francis HC, Chapman MD, Woodcock A. Exposure to house dust mite allergens and the clinical activity of asthma. J Allergy Clin Immunol 1996;98:6472.
  • 65
    Yssel H, Abbal C, Pene J, Bousquet J. The role of IgE in asthma. Clin Exp Allergy 1998;28:104109; discussion 117–118.
  • 66
    Pearce N, Douwes J, Beasley R. Is allergen exposure the major primary cause of asthma? Thorax 2000;55:424431.
  • 67
    Suphioglu C, Singh MB, Taylor P, Bellomo R, Holmes P, Puy R et al. Mechanism of grass-pollen-induced asthma. Lancet 1992;339:569572.
  • 68
    Anto JM, Sunyer J, Rodriguez-Roisin R, Suarez-Cervera M, Vazquez L. Community outbreaks of asthma associated with inhalation of soybean dust. Toxicoepidemiological Committee. N Engl J Med 1989;320:10971102.
  • 69
    Sporik R, Platts-Mills TA, Cogswell JJ. Exposure to house dust mite allergen of children admitted to hospital with asthma. Clin Exp Allergy 1993;23:740746.
  • 70
    Djukanovic R, Feather I, Gratziou C, Walls A, Peroni D, Bradding P et al. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax 1996;51:575581.
  • 71
    Bousquet J, Boushey HA, Busse WW, Canonica GW, Durham SR, Irvin CG et al. Characteristics of patients with seasonal allergic rhinitis and concomitant asthma. Clin Exp Allergy 2004;34:897903.
  • 72
    Bentley AM, Kay AB, Durham SR. Human late asthmatic reactions. Clin Exp Allergy 1997;31:7186.
  • 73
    De Kluijver J, Evertse CE, Schrumpf JA, Van Der Veen H, Zwinderman AH, Hiemstra PS et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: protection by inhaled steroids. Am J Respir Crit Care Med 2002;166:294300.
  • 74
    Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case–control study. BMJ 2002;324:763.
  • 75
    Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994;94:22002208.
  • 76
    De Kluijver J, Evertse CE, Sont JK, Schrumpf JA, Van Zeijl-van der Ham CJ, Dick CR et al. Are rhinovirus-induced airway responses in asthma aggravated by chronic allergen exposure? Am J Respir Crit Care Med 2003;168:11741180.
  • 77
    Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836844.
  • 78
    O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129136.
  • 79
    Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246256.
  • 80
    Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327:891.
  • 81
    Holgate ST, Holloway J, Wilson S, Howarth PH, Haitchi HM, Babu S et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006;117:496506.
  • 82
    Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment). Allergy 2005;60:309316.
  • 83
    Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302308.
  • 84
    Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:10121018.
  • 85
    Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354:754758.